Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions - PubMed (original) (raw)

Review

Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions

Hui Zhang et al. Front Med (Lausanne). 2025.

Abstract

Diabetic kidney disease (DKD) has emerged as the leading cause of chronic kidney disease (CKD) worldwide, surpassing primary glomerular disorders in prevalence. Despite recent therapeutic advances, current treatment strategies primarily alleviate symptoms rather than address the underlying pathogenic mechanisms, highlighting an urgent need for targeted, mechanism-based interventions. The pathogenesis of DKD involves a complex interplay of metabolic, hemodynamic, inflammatory, oxidative, and fibrotic pathways. Chronic hyperglycemia initiates a cascade of molecular events-including the accumulation of advanced glycation end products (AGEs), activation of the polyol pathway, enhanced protein kinase C (PKC) signaling, and mitochondrial dysfunction-culminating in glomerular hyperfiltration, podocyte injury, and progressive glomerular and tubulointerstitial fibrosis. In addition to these classical mechanisms, emerging processes such as ferroptosis (iron-dependent cell death), impaired autophagy, gut microbiota dysbiosis, and epigenetic alterations offer promising therapeutic targets. Current DKD management integrates lifestyle modifications with four cornerstone pharmacologic classes: renin-angiotensin-aldosterone system inhibitors (RAASi), sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and mineralocorticoid receptor antagonists (MRAs). Notably, evidence from clinical trials suggests that simultaneous modulation of multiple pathogenic pathways provides superior cardiorenal protection compared to monotherapy. Investigational therapies-including endothelin receptor antagonists (ERAs), nuclear factor erythroid 2-related factor 2 (Nrf2) activators, and gut microbiota modulators-are under active evaluation. Additionally, Traditional Chinese Medicine (TCM) formulations have demonstrated albuminuria-lowering effects in clinical studies. Future research should prioritize biomarker-driven precision medicine approaches, enabling individualized therapy selection and development of agents that concurrently target ferroptosis and inflammation. Given the multifaceted pathophysiology of DKD, optimal management will require multimodal, patient-tailored regimens that address hyperglycemia, hypertension, inflammation, and fibrosis to effectively slow or halt disease progression.

Keywords: cardiorenal protection; diabetic kidney disease (DKD); finerenone; gut-kidney axis; sodium-glucose co-transporter 2 inhibitors (SGLT2i).

Copyright © 2025 Zhang, Wang, Zhao, Qin, Cai, Wu, Li and Wang.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1

Figure 1

Oxidative stress pathways in DKD. This figure depicts the role of oxidative stress in DKD pathogenesis. Hyperglycemia induces excessive ROS production via NADPH oxidase (NOX4/5), mitochondrial dysfunction, and xanthine oxidase. ROS promotes lipid peroxidation, DNA damage, ferroptosis, and ER stress. AGE–RAGE signaling amplifies ROS, while Nrf2–Keap1 pathway and antioxidant enzymes (SOD, CAT, and GSH-Px) are inhibited, exacerbating oxidative damage in glomerular and tubulointerstitial compartments. ROS, reactive oxygen species; AGEs, advanced glycation end-products; RAGE, receptor for AGEs; NOX, NADPH oxidase isoforms; MDA, malondialdehyde; 4-HNE, 4-hydroxynonenal; 8-OHdG Kelch-like ECH, 8-hydroxy-2′-deoxyguanosine; SOD, superoxide dismutase; CAT, catalase; GSH-Px, glutathione peroxidase; Nrf2, nuclear factor erythroid 2–related factor 2; Keap1, Kelch-like ECH-associated protein 1; ER, endoplasmic reticulum.

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group . KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. (2022) 102:S1–127. 10.1016/j.kint.2022.06.008 - DOI - PubMed
    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. (2022) 183:109119. 10.1016/j.diabres.2021.109119 - DOI - PMC - PubMed
    1. Gheith O, Othman N, Nampoory N, Halimb MA, Al-Otaibi T. Diabetic kidney disease: difference in the prevalence and risk factors worldwide. J Egypt Soc Nephrol Transplant. (2016) 16:65. 10.4103/1110-9165.197379 - DOI
    1. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. (2013) 24:302–8. 10.1681/ASN.2012070718 - DOI - PMC - PubMed
    1. van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, et al. Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. (2024) 20:433–46. 10.1038/s41581-024-00827-z - DOI - PubMed

Publication types

LinkOut - more resources